Nakamuta, Makoto

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population

Nakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., Nakamura, H., Komori, A., Nakamuta, M., Zeniya, M., et al. (2012) · The American Journal of Human Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 267

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

Honda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 210

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Cordell, H. J., Fryett, J. J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., Kawashima, M., Nishida, N., Khor, S.-S., Gervais, O., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 182

Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity

Kubota, N., Kubota, T., Kajiwara, E., Iwamura, T., Kumagai, H., Watanabe, T., Inoue, M., Takamoto, I., Sasako, T., Kumagai, K., et al. (2016) · Nature Communications

Metabolism, Diabetes, and CancerPancreatic function and diabetes

Cited by 143

A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats

Tada, S., Iwamoto, H., Nakamuta, M., Sugimoto, R., Enjoji, M., Nakashima, Y., & Nawata, H. (2001) · Journal of Hepatology

Liver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

Cited by 102

Fenofibrate for patients with asymptomatic primary biliary cirrhosis

Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H., & Yamamoto, K. (2004) · World Journal of Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 99

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

Asselta, R., Paraboschi, E. M., Gerussi, A., Cordell, H. J., Mells, G. F., Sandford, R. N., Jones, D. E., Nakamura, M., Ueno, K., Hitomi, Y., et al. (2021) · Gastroenterology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 55

Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population

Kawashima, M., Hitomi, Y., Aiba, Y., Nishida, N., Kojima, K., Kawai, Y., Nakamura, H., Tanaka, A., Zeniya, M., Hashimoto, E., et al. (2017) · Human Molecular Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 52

Long‐term fibrate treatment for PBC

Nakamuta, M., Enjoji, M., Kotoh, K., Shimohashi, N., & Tanabe, Y. (2005) · Journal of Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 26